Skip to Content

  • Search

View Additional Section Content

CALGB 40302 – Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer.

Clinical Trial Categories

  • Breast Cancer
The Rosenfeld Cancer Center at 215-481-2402


  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details